ROCKLATAN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Rocklatan, and when can generic versions of Rocklatan launch?
Rocklatan is a drug marketed by Alcon Labs Inc and is included in one NDA. There are sixteen patents protecting this drug and one Paragraph IV challenge.
This drug has sixty-seven patent family members in fourteen countries.
The generic ingredient in ROCKLATAN is latanoprost; netarsudil dimesylate. There are twenty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the latanoprost; netarsudil dimesylate profile page.
DrugPatentWatch® Generic Entry Outlook for Rocklatan
Rocklatan was eligible for patent challenges on December 18, 2021.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be March 14, 2034. This may change due to patent challenges or generic licensing.
There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.
Indicators of Generic Entry
Summary for ROCKLATAN
International Patents: | 67 |
US Patents: | 16 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Clinical Trials: | 1 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for ROCKLATAN |
What excipients (inactive ingredients) are in ROCKLATAN? | ROCKLATAN excipients list |
DailyMed Link: | ROCKLATAN at DailyMed |


DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ROCKLATAN
Generic Entry Date for ROCKLATAN*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION/DROPS;OPHTHALMIC |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for ROCKLATAN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Aerie Pharmaceuticals | Phase 4 |
Pharmacology for ROCKLATAN
Drug Class | Prostaglandin Analog Rho Kinase Inhibitor |
Mechanism of Action | Rho Kinase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for ROCKLATAN
Paragraph IV (Patent) Challenges for ROCKLATAN
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
ROCKLATAN | Ophthalmic Solution | latanoprost; netarsudil dimesylate | 0.005%/0.02% | 208259 | 2 | 2021-12-20 |
US Patents and Regulatory Information for ROCKLATAN
ROCKLATAN is protected by sixteen US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of ROCKLATAN is ⤷ Try a Trial.
This potential generic entry date is based on patent ⤷ Try a Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting ROCKLATAN
Dual mechanism inhibitors for the treatment of disease
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
Combination therapy
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
Dual mechanism inhibitors for the treatment of disease
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
Dual mechanism inhibitors for the treatment of disease
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
Compositions for treating glaucoma or reducing intraocular pressure
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Combination therapy
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
Dual mechanism inhibitors for the treatment of disease
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
Combination therapy
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Combination therapy
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
Combination therapy
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alcon Labs Inc | ROCKLATAN | latanoprost; netarsudil dimesylate | SOLUTION/DROPS;OPHTHALMIC | 208259-001 | Mar 12, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Alcon Labs Inc | ROCKLATAN | latanoprost; netarsudil dimesylate | SOLUTION/DROPS;OPHTHALMIC | 208259-001 | Mar 12, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Alcon Labs Inc | ROCKLATAN | latanoprost; netarsudil dimesylate | SOLUTION/DROPS;OPHTHALMIC | 208259-001 | Mar 12, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Alcon Labs Inc | ROCKLATAN | latanoprost; netarsudil dimesylate | SOLUTION/DROPS;OPHTHALMIC | 208259-001 | Mar 12, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Alcon Labs Inc | ROCKLATAN | latanoprost; netarsudil dimesylate | SOLUTION/DROPS;OPHTHALMIC | 208259-001 | Mar 12, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ROCKLATAN
When does loss-of-exclusivity occur for ROCKLATAN?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 14228790
Estimated Expiration: ⤷ Try a Trial
Patent: 18202965
Estimated Expiration: ⤷ Try a Trial
Patent: 18202990
Estimated Expiration: ⤷ Try a Trial
Patent: 20203976
Estimated Expiration: ⤷ Try a Trial
Canada
Patent: 05089
Estimated Expiration: ⤷ Try a Trial
China
Patent: 5263494
Estimated Expiration: ⤷ Try a Trial
Patent: 9528721
Estimated Expiration: ⤷ Try a Trial
Patent: 0396085
Estimated Expiration: ⤷ Try a Trial
European Patent Office
Patent: 76080
Estimated Expiration: ⤷ Try a Trial
Patent: 61484
Estimated Expiration: ⤷ Try a Trial
Patent: 11943
Estimated Expiration: ⤷ Try a Trial
Japan
Patent: 16515520
Estimated Expiration: ⤷ Try a Trial
Patent: 19094339
Estimated Expiration: ⤷ Try a Trial
Patent: 20125355
Estimated Expiration: ⤷ Try a Trial
Patent: 20143163
Estimated Expiration: ⤷ Try a Trial
Patent: 21046439
Estimated Expiration: ⤷ Try a Trial
Netherlands
Patent: 1101
Estimated Expiration: ⤷ Try a Trial
Spain
Patent: 76199
Estimated Expiration: ⤷ Try a Trial
Patent: 52377
Estimated Expiration: ⤷ Try a Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering ROCKLATAN around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | 2020125355 | 併用療法 (COMBINATION THERAPY) | ⤷ Try a Trial |
Japan | 2020143163 | 併用療法 (COMBINATION THERAPY) | ⤷ Try a Trial |
Poland | 3811943 | ⤷ Try a Trial | |
Australia | 2010242800 | Dual-action inhibitors and methods of using same | ⤷ Try a Trial |
Japan | 2016515520 | 併用療法 | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ROCKLATAN
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3053913 | 301038 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: NETARSUDIL, OF EEN ZOUT OF SOLVAAAT DAARVAN, IN HET BIJZONDER NETARSUDILMESYLAAT; REGISTRATION NO/DATE: EU/1/19/1400 20191121 |
3053913 | C202030018 | Spain | ⤷ Try a Trial | PRODUCT NAME: NETARSUDIL O UN ENANTIOMERO, DIASTEREOMERO, SAL O SOLVATO DEL MISMO.; NATIONAL AUTHORISATION NUMBER: EU/1/19/1400; DATE OF AUTHORISATION: 20191119; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/19/1400; DATE OF FIRST AUTHORISATION IN EEA: 20191119 |
3461484 | 132021000000068 | Italy | ⤷ Try a Trial | PRODUCT NAME: COMBINAZIONE DI LATANOPROST E NETARSUDIL(ROCLANDA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1502, 20210108 |
3461484 | 122021000036 | Germany | ⤷ Try a Trial | PRODUCT NAME: LATANOPROST, ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, UND NETARSUDIL MESYLAT; REGISTRATION NO/DATE: EU/1/20/1502 20210107 |
3053913 | 2020/016 | Ireland | ⤷ Try a Trial | PRODUCT NAME: NETARSUDIL, OR AN ENANTIOMER, DIASTEREOMER, SALT OR SOLVATE THEREOF; REGISTRATION NO/DATE: EU/1/19/1400 20191121 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |